表紙
市場調査レポート

腫瘍アブレーションの世界市場の予測 (〜2020年):技術 (高周波・マイクロ波・冷凍・IRE・超音波)・治療モード (外科的・腹腔鏡下・経皮的)・対象疾患別

Tumor Ablation Market by Technology (Radiofrequency, Microwave, Cryoablation, IRE, Ultrasound), Mode of treatment (Surgical, Laparoscopic, Percutaneous), Application (Liver, Lung, Kidney, Bone Metastasis, Prostate, Breast) - Global Forecasts to 2020

発行 MarketsandMarkets 商品コード 335087
出版日 ページ情報 英文 242 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
腫瘍アブレーションの世界市場の予測 (〜2020年):技術 (高周波・マイクロ波・冷凍・IRE・超音波)・治療モード (外科的・腹腔鏡下・経皮的)・対象疾患別 Tumor Ablation Market by Technology (Radiofrequency, Microwave, Cryoablation, IRE, Ultrasound), Mode of treatment (Surgical, Laparoscopic, Percutaneous), Application (Liver, Lung, Kidney, Bone Metastasis, Prostate, Breast) - Global Forecasts to 2020
出版日: 2015年03月26日 ページ情報: 英文 242 Pages
概要

世界の腫瘍アブレーション市場は2015年〜2020年にかけて11.5%のCAGRで推移し、2020年には5億1520万ドルの規模に成長すると予測されています。現在は米国、ドイツ、フランス、英国などといった成熟市場が最大のシェアを占めているものの、今後はアジア太平洋地域が最大の成長を遂げると予測されています。世界的な高齢化や癌患者数の増加、技術的進歩、病院・アブレーションセンターなどの施設の増加、他の治療や外科的処置と比較したアブレーション処置のメリットに対する認知度の拡大などが同市場の成長を促す要因となっています。

当レポートでは、世界の腫瘍アブレーションの市場について調査し、産業構造とバリューチェーン、市場成長への各種影響因子および市場機会の分析、アブレーション技術・治療モード・対象疾患別の市場分析および市場成長予測、地域および主要国の動向、競合環境と市場シェア、主要企業のプロファイルなどをまとめています。

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

  • 市場機会
  • 北米:最大の市場シェア
  • 中国・インド:今後の市場成長を牽引
  • 中国・インド:マイクロ波・冷凍アブレーション製品を需要を牽引
  • 北米:現在の肝臓癌アブレーション市場において最大のシェア
  • MEDTRONIC・PLC:腫瘍アブレーション市場で独占的立場

第5章 市場概要

  • イントロダクション
  • 市場区分
  • 市場の発展の推移
  • 市場力学
    • 概要
    • 影響分析
    • 成長推進因子
    • 成長阻害因子
    • 市場機会
    • 課題

第6章 産業分析

  • イントロダクション
  • バリューチェーン分析
  • 産業動向
  • ポーターのファイブフォース分析

第7章 腫瘍アブレーション市場:技術別

  • イントロダクション
  • 高周波アブレーション
  • マイクロ波アブレーション
  • 冷凍アブレーション
  • その他

第8章 腫瘍アブレーション市場:治療モード別

  • イントロダクション
  • 外科的アブレーション
  • 腹腔鏡下アブレーション
  • 経皮的アブレーション

第9章 腫瘍アブレーション市場:用途別

  • イントロダクション
  • 肝臓癌アブレーション
  • 肺癌アブレーション
  • 腎臓癌アブレーション
  • 骨転移腫瘍アブレーション
  • その他

第10章 腫瘍アブレーション市場:地域別

  • イントロダクション
  • 北米
    • 米国
    • カナダ
  • 欧州
    • イタリア
    • ドイツ
    • フランス
    • 英国
    • スペイン
    • その他
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • その他
  • その他

第11章 競合環境

  • イントロダクション
  • 市場シェア分析
  • 競合シナリオ
  • 禁煙の発展動向
    • パイプライン開発・製品の強化
    • 投資撤退・買収
    • 地域的拡張
    • 合意・提携・協力
    • その他

第12章 企業プロファイル

  • イントロダクション
  • MEDTRONIC, PLC (米国)
  • ANGIODYNAMICS, INC. (米国)
  • HEALTHTRONICS, INC. (米国)
  • GALIL MEDICAL, INC. (米国)
  • BOSTON SCIENTIFIC CORPORATION (米国)
  • NEUWAVE MEDICAL, INC. (米国)
  • EDAP TMS S.A. (フランス)
  • MERMAID MEDICAL, INC. (デンマーク)
  • SONACARE MEDICAL, LLC (米国)
  • MESONIX, INC. (米国)

第13章 付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: MD 3271

The global tumor ablation market is poised to grow at a CAGR of 11.5% during the forecast period (2015-2020), and is expected to reach a value of ~515.2 million by 2020. Although mature markets (such as the U.S., Germany, France, and the U.K.) hold larger shares in the tumor ablation market, the Asia-Pacific region is expected to grow at the highest CAGR in the forecast period. Growth in the tumor ablation market is driven by factors such as growing geriatric population across the world, increasing population base for cancer patients, technological advancements in ablation devices, increasing number of hospitals and surgical and ablation centers, and growing awareness regarding the benefits offered by ablation procedures over those of conventional therapeutic and surgical procedures. However, factors such as cost-containment measures taken by various governments and ongoing healthcare reforms in the U.S. are restraining the growth of this market. In addition, therapeutic challenges related to ablation procedures and stringent regulatory guidelines leading to significant increase in gestation period of product launches are posing significant challenges for the growth of the tumor ablation market.

In this report, the global tumor ablation market is segmented on the basis of technology (radiofrequency ablation, microwave ablation, cryoablation, and other technologies), mode of treatment (surgical, laparoscopic, and percutaneous ablation), and application (liver cancer, lung cancer, kidney cancer, bone metastasis, and other applications). The radiofrequency ablation technology segment accounted for the largest share of the global tumor ablation market in 2014, followed by the microwave ablation technology market. Factors such as significant awareness in the medical community about the application of radiofrequency ablation in cancer treatments, presence of a large number of radiofrequency ablation centers across the globe, and low procedural costs associated with radiofrequency tumor ablation are driving the growth of the radiofrequency tumor ablation market.

Geographically, North America (comprising the U.S. and Canada) commands the largest share of the global tumor ablation market in 2014, followed by Europe. The tumor ablation market in North America is primarily driven by factors such as early introduction and high adoption rate of tumor ablation products in the region, significant trend of replacing older technologies with advanced and innovative therapeutic techniques (such as microwave ablation and cryoablation), and increasing private/public funding to develop and commercialize novel tumor ablation products. However, financial constraints faced by market players are limiting the growth of the tumor ablation market in this region. The Asia-Pacific region is poised to grow at the highest CAGR in the next five years, owing to factors such as large population base paired with high prevalence of various cancers (such as liver, lung, and kidney) in the region, ongoing government initiatives for development and modernization of healthcare infrastructure, increasing adoption due to continuously decreasing prices of tumor ablation products, and rising trends related to localized manufacturing due to growing focus of global giants in the APAC market.

The global tumor ablation market is moderately competitive with various global as well as local market players. As of 2014, the global tumor ablation market was dominated by Medtronic, plc (U.S.), AngioDynamics, Inc. (U.S.), HealthTronics, Inc. (U.S.), Galil Medical, Inc. (U.S.), and Boston Scientific Corporation (U.S.) that together accounted for ~83.0% of the market. New product launches; partnerships, agreements, and collaborations; and strategic acquisitions are the major strategies adopted by most of the market players to achieve growth in the global tumor ablation market.

Reasons to Buy the Report:

From an insight perspective, this research report has focused on various levels of analysis such as industry analysis (industry trends and Porter's five force model), market share analysis of top ten players, and company profiles, which together comprise and discuss the basic views on the competitive landscape, emerging and high-growth segments of the tumor ablation market, and high-growth regions and their respective drivers, restraints, challenges, and opportunities.

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn helped firms garner higher market shares. Firms purchasing the report could use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on tumor ablation products offered by the top 10 players in the global tumor ablation market. The report analyzes the tumor ablation market by technology, mode of treatment, and application across key geographic regions
  • Product Development/Innovation: Detailed insights on upcoming tumor ablation technologies, research and development activities, and new product launches in the global tumor ablation market
  • Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various tumor ablation products across key geographic regions
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the global tumor ablation market
  • Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of leading players in the global tumor ablation market

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
  • 1.3. MARKET SCOPE
    • 1.3.1. MARKETS COVERED
    • 1.3.2. GEOGRAPHIC SCOPE
  • 1.4. LIMITATIONS
  • 1.5. STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. RESEARCH DATA
    • 2.1.1. SECONDARY DATA
      • 2.1.1.1. KEY DATA FROM SECONDARY SOURCES
    • 2.1.2. PRIMARY DATA
      • 2.1.2.1. KEY DATA FROM PRIMARY SOURCES
  • 2.2. MARKET SIZE ESTIMATION
    • 2.2.1. TOP-DOWN APPROACH
    • 2.2.2. BOTTOM-UP APPROACH
  • 2.3. MARKET BREAKDOWN AND DATA TRIANGULATION
  • 2.4. RESEARCH ASSUMPTIONS

3. EXECUTIVE SUMMARY

  • 3.1. INTRODUCTION
  • 3.2. CURRENT MARKET SCENARIO
  • 3.3. FUTURE OUTLOOK
  • 3.4. CONCLUSION

4. PREMIUM INSIGHTS

  • 4.1. MARKET OPPORTUNITIES FOR GROWTH IN TUMOR ABLATION MARKET (2015-2020)
  • 4.2. NORTH AMERICA TO COMMAND THE LARGEST SHARE OF TUMOR ABLATION MARKET FOR SURGICAL MODE OF TREATMENT, IN 2015
  • 4.3. CHINA AND INDIA TO LEAD THE MARKET GROWTH FOR TUMOR ABLATION TECHNOLOGIES DURING THE FORECAST PERIOD
  • 4.4. CHINA AND INDIA TO LEAD THE MARKET DEMAND FOR MICROWAVE AND CRYOABLATION-BASED TUMOR ABLATION PRODUCTS
  • 4.5. NORTH AMERICA TO HOLD THE LARGEST SHARE OF LIVER CANCER ABLATION MARKET IN 2015
  • 4.6. MEDTRONIC, PLC DOMINATED THE TUMOR ABLATION MARKET IN 2014

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
  • 5.2. MARKET SEGMENTATION
  • 5.3. MARKET EVOLUTION
  • 5.4. MARKET DYNAMICS
    • 5.4.1. OVERVIEW
    • 5.4.2. IMPACT ANALYSIS
    • 5.4.3. KEY MARKET DRIVERS
      • 5.4.3.1. GROWING GERIATRIC POPULATION ACROSS THE GLOBE
      • 5.4.3.2. INCREASING POPULATION OF CANCER PATIENTS
      • 5.4.3.3. CONTINUOUS TECHNOLOGICAL ADVANCEMENTS IN TUMOR ABLATION PRODUCTS
      • 5.4.3.4. INCREASING NUMBER OF HOSPITALS, AND SURGICAL AND ABLATION CENTERS
    • 5.4.4. KEY MARKET RESTRAINTS
      • 5.4.4.1. COST CONTAINMENT MEASURES TAKEN BY VARIOUS GOVERNMENTS
      • 5.4.4.2. ONGOING HEALTHCARE REFORMS IN THE U.S.
    • 5.4.5. KEY MARKET OPPORTUNITIES
      • 5.4.5.1. EMERGING MARKETS
      • 5.4.5.2. GROWING AWARENESS OF ABLATION PROCEDURES
      • 5.4.5.3. CHANGING REIMBURSEMENT LANDSCAPE
    • 5.4.6. KEY MARKET CHALLENGES
      • 5.4.6.1. STRINGENT REGULATORY GUIDELINES

6. INDUSTRY INSIGHTS

  • 6.1. INTRODUCTION
  • 6.2. VALUE CHAIN ANALYSIS
  • 6.3. INDUSTRY TRENDS
    • 6.3.1. GROWING ADOPTION RATE OF RADIOFREQUENCY-BASED TUMOR ABLATION PROCEDURES
    • 6.3.2. GROWING MARKET FOCUS ON THE DEVELOPMENT OF NOVEL MICROWAVE-BASED TUMOR ABLATION PRODUCTS
  • 6.4. PORTER'S FIVE FORCE ANALYSIS
    • 6.4.1. OVERVIEW
    • 6.4.2. THREAT FROM NEW ENTRANTS
    • 6.4.3. THREAT OF SUBSTITUTES
    • 6.4.4. BARGAINING POWER OF SUPPLIERS
    • 6.4.5. BARGAINING POWER OF BUYERS
    • 6.4.6. INTENSITY OF COMPETITIVE RIVALRY

7. TUMOR ABLATION MARKET, BY TECHNOLOGY

  • 7.1. INTRODUCTION
  • 7.2. RADIOFREQUENCY (RF) ABLATION
  • 7.3. MICROWAVE ABLATION
  • 7.4. CRYOABLATION
  • 7.5. OTHER TECHNOLOGIES

8. TUMOR ABLATION MARKET, BY MODE OF TREATMENT

  • 8.1. INTRODUCTION
  • 8.2. SURGICAL ABLATION
  • 8.3. LAPAROSCOPIC ABLATION
  • 8.4. PERCUTANEOUS ABLATION

9. TUMOR ABLATION MARKET, BY APPLICATION

  • 9.1. INTRODUCTION
  • 9.2. LIVER CANCER ABLATION
  • 9.3. LUNG CANCER ABLATION
  • 9.4. KIDNEY CANCER ABLATION
  • 9.5. BONE METASTASIS ABLATION
  • 9.6. OTHER APPLICATIONS

10. TUMOR ABLATION MARKET, BY REGION

  • 10.1. INTRODUCTION
  • 10.2. NORTH AMERICA
    • 10.2.1. U.S.
    • 10.2.2. CANADA
  • 10.3. EUROPE
    • 10.3.1. ITALY
    • 10.3.2. GERMANY
    • 10.3.3. FRANCE
    • 10.3.4. U.K.
    • 10.3.5. SPAIN
    • 10.3.6. REST OF EUROPE (ROE)
  • 10.4. ASIA-PACIFIC
    • 10.4.1. JAPAN
    • 10.4.2. CHINA
    • 10.4.3. INDIA
    • 10.4.4. REST OF ASIA-PACIFIC (ROAPAC)
  • 10.5. REST OF THE WORLD (ROW)

11. COMPETITIVE LANDSCAPE

  • 11.1. INTRODUCTION
  • 11.2. MARKET SHARE ANALYSIS
  • 11.3. COMPETITIVE SCENARIO
  • 11.4. RECENT DEVELOPMENTS
    • 11.4.1. PIPELINE DEVELOPMENTS AND PRODUCT ENHANCEMENTS
    • 11.4.2. DIVESTMENTS AND ACQUISITIONS
    • 11.4.3. GEOGRAPHIC EXPANSION
    • 11.4.4. AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS
    • 11.4.5. OTHER DEVELOPMENTS

12. COMPANY PROFILES

  • 12.1. INTRODUCTION
    • 12.1.1. GEOGRAPHIC BENCHMARKING
    • 12.1.2. KEY GROWTH STRATEGY ADOPTED BY MARKET PLAYERS
  • 12.2. MEDTRONIC, PLC (U.S.)
  • 12.3. ANGIODYNAMICS, INC. (U.S.)
  • 12.4. HEALTHTRONICS, INC. (U.S.)
  • 12.5. GALIL MEDICAL, INC. (U.S.)
  • 12.6. BOSTON SCIENTIFIC CORPORATION (U.S.)
  • 12.7. NEUWAVE MEDICAL, INC. (U.S.)
  • 12.8. EDAP TMS S.A. (FRANCE)
  • 12.9. MERMAID MEDICAL, INC. (DENMARK)
  • 12.10. SONACARE MEDICAL, LLC (U.S.)
  • 12.11. MESONIX, INC. (U.S.)

13. APPENDIX

  • 13.1. INSIGHTS FROM INDUSTRY EXPERTS
  • 13.2. DISCUSSION GUIDE
  • 13.3. INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
    • 13.3.1. VALUE CHAIN
  • 13.4. AVAILABLE CUSTOMIZATIONS
  • 13.5. RELATED REPORTS

LIST OF TABLES

  • TABLE 1: GLOBAL TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2013-2020 ($MILLION)
  • TABLE 2: TUMOR ABLATION MARKET SIZE FOR RF ABLATION TECHNOLOGY, BY REGION, 2013-2020 ($MILLION)
  • TABLE 3: TUMOR ABLATION MARKET SIZE FOR MICROWAVE ABLATION TECHNOLOGY, BY REGION, 2013-2020 ($MILLION)
  • TABLE 4: TUMOR ABLATION MARKET SIZE FOR CRYOABLATION TECHNOLOGY, BY REGION, 2013-2020 ($MILLION)
  • TABLE 5: TUMOR ABLATION MARKET SIZE FOR OTHER TECHNOLOGIES, BY REGION, 2013-2020 ($MILLION)
  • TABLE 6: GLOBAL TUMOR ABLATION MARKET SIZE, BY MODE OF TREATMENT, 2013-2020 ($MILLION)
  • TABLE 7: CLINICAL PERSPECTIVE OF KEY HEPATOCELLULAR CARCINOMA SURGICAL TREATMENT MODES - A COMPARATIVE STUDY
  • TABLE 8: TUMOR ABLATION MARKET SIZE FOR SURGICAL MODE OF TREATMENT, BY REGION, 2013-2020 ($MILLION)
  • TABLE 9: TUMOR ABLATION MARKET SIZE FOR LAPAROSCOPIC MODE OF TREATMENT, BY REGION, 2013-2020 ($MILLION)
  • TABLE 10: TUMOR ABLATION MARKET SIZE FOR PERCUTANEOUS MODE OF TREATMENT, BY REGION, 2013-2020 ($MILLION)
  • TABLE 11: KEY PERCUTANEOUS TUMOR ABLATION TECHNOLOGIES - A COMPARATIVE STUDY
  • TABLE 12: GLOBAL TUMOR ABLATION MARKET SIZE, BY APPLICATION, 2013-2020 ($MILLION)
  • TABLE 13: TUMOR ABLATION MARKET SIZE FOR LIVER CANCER APPLICATION, BY REGION, 2013-2020 ($MILLION)
  • TABLE 14: LIVER CANCER ABLATION MARKET-INFLUENCING FACTORS
  • TABLE 15: TUMOR ABLATION MARKET SIZE FOR LUNG CANCER APPLICATION, BY REGION, 2013-2020 ($MILLION)
  • TABLE 16: LUNG CANCER ABLATION MARKET-INFLUENCING FACTORS
  • TABLE 17: TUMOR ABLATION MARKET SIZE FOR KIDNEY CANCER APPLICATION, BY REGION, 2013-2020 ($MILLION)
  • TABLE 18: KIDNEY CANCER ABLATION MARKET-INFLUENCING FACTORS
  • TABLE 19: TUMOR ABLATION MARKET SIZE FOR BONE METASTASIS APPLICATION, BY REGION, 2013-2020 ($MILLION)
  • TABLE 20: BONE METASTASIS ABLATION MARKET-INFLUENCING FACTORS
  • TABLE 21: TUMOR ABLATION MARKET SIZE FOR OTHER APPLICATIONS, BY REGION, 2013-2020 ($MILLION)
  • TABLE 22: GLOBAL TUMOR ABLATION MARKET SIZE, BY REGION, 2013-2020 ($MILLION)
  • TABLE 23: NORTH AMERICA: TUMOR ABLATION MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 24: NORTH AMERICA: TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2013-2020 ($MILLION)
  • TABLE 25: NORTH AMERICA: TUMOR ABLATION MARKET SIZE, BY MODE OF TREATMENT, 2013-2020 ($MILLION)
  • TABLE 26: NORTH AMERICA: TUMOR ABLATION MARKET SIZE, BY APPLICATION, 2013-2020 ($MILLION)
  • TABLE 27: U.S.: TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2013-2020 ($MILLION)
  • TABLE 28: U.S.: TUMOR ABLATION MARKET SIZE, BY MODE OF TREATMENT, 2013-2020 ($MILLION)
  • TABLE 29: U.S.: TUMOR ABLATION MARKET SIZE, BY APPLICATION, 2013-2020 ($MILLION)
  • TABLE 30: CANADA: TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2013-2020 ($MILLION)
  • TABLE 31: CANADA: TUMOR ABLATION MARKET SIZE, BY MODE OF TREATMENT, 2013-2020 ($MILLION)
  • TABLE 32: CANADA: TUMOR ABLATION MARKET SIZE, BY APPLICATION, 2013-2020 ($MILLION)
  • TABLE 33: EUROPE: TUMOR ABLATION MARKET SIZE, BY COUNTRY/REGION, 2013-2020 ($MILLION)
  • TABLE 34: EUROPE: TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2013-2020 ($MILLION)
  • TABLE 35: EUROPE: TUMOR ABLATION MARKET SIZE, BY MODE OF TREATMENT, 2013-2020 ($MILLION)
  • TABLE 36: EUROPE: TUMOR ABLATION MARKET SIZE, BY APPLICATION, 2013-2020 ($MILLION)
  • TABLE 37: ITALY: TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2013-2020 ($MILLION)
  • TABLE 38: ITALY: TUMOR ABLATION MARKET SIZE, BY MODE OF TREATMENT, 2013-2020 ($MILLION)
  • TABLE 39: ITALY: TUMOR ABLATION MARKET SIZE, BY APPLICATION, 2013-2020 ($MILLION)
  • TABLE 40: GERMANY: TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2013-2020 ($MILLION)
  • TABLE 41: GERMANY: TUMOR ABLATION MARKET SIZE, BY MODE OF TREATMENT, 2013-2020 ($MILLION)
  • TABLE 42: GERMANY: TUMOR ABLATION MARKET SIZE, BY APPLICATION, 2013-2020 ($MILLION)
  • TABLE 43: FRANCE: TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2013-2020 ($MILLION)
  • TABLE 44: FRANCE: TUMOR ABLATION MARKET SIZE, BY MODE OF TREATMENT, 2013-2020 ($MILLION)
  • TABLE 45: FRANCE: TUMOR ABLATION MARKET SIZE, BY APPLICATION, 2013-2020 ($MILLION)
  • TABLE 46: U.K.: TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2013-2020 ($MILLION)
  • TABLE 47: U.K.: TUMOR ABLATION MARKET SIZE, BY MODE OF TREATMENT, 2013-2020 ($MILLION)
  • TABLE 48: U.K.: TUMOR ABLATION MARKET SIZE, BY APPLICATION, 2013-2020 ($MILLION)
  • TABLE 49: SPAIN: TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2013-2020 ($MILLION)
  • TABLE 50: SPAIN: TUMOR ABLATION MARKET SIZE, BY MODE OF TREATMENT, 2013-2020 ($MILLION)
  • TABLE 51: SPAIN: TUMOR ABLATION MARKET SIZE, BY APPLICATION, 2013-2020 ($MILLION)
  • TABLE 52: ROE: TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2013-2020 ($MILLION)
  • TABLE 53: ROE: TUMOR ABLATION MARKET SIZE, BY MODE OF TREATMENT, 2013-2020 ($MILLION)
  • TABLE 54: ROE: TUMOR ABLATION MARKET SIZE, BY APPLICATION, 2013-2020 ($MILLION)
  • TABLE 55: ASIA-PACIFIC: TUMOR ABLATION MARKET SIZE, BY COUNTRY/REGION, 2013-2020 ($MILLION)
  • TABLE 56: ASIA-PACIFIC: TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2013-2020 ($MILLION)
  • TABLE 57: ASIA-PACIFIC: TUMOR ABLATION MARKET SIZE, BY MODE OF TREATMENT, 2013-2020 ($MILLION)
  • TABLE 58: ASIA-PACIFIC: TUMOR ABLATION MARKET SIZE, BY APPLICATION, 2013-2020 ($MILLION)
  • TABLE 59: JAPAN: TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2013-2020 ($MILLION)
  • TABLE 60: JAPAN: TUMOR ABLATION MARKET SIZE, BY MODE OF TREATMENT, 2013-2020 ($MILLION)
  • TABLE 61: JAPAN: TUMOR ABLATION MARKET SIZE, BY APPLICATION, 2013-2020 ($MILLION)
  • TABLE 62: CHINA: TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2013-2020 ($MILLION)
  • TABLE 63: CHINA: TUMOR ABLATION MARKET SIZE, BY MODE OF TREATMENT, 2013-2020 ($MILLION)
  • TABLE 64: CHINA: TUMOR ABLATION MARKET SIZE, BY APPLICATION, 2013-2020 ($MILLION)
  • TABLE 65: INDIA: TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2013-2020 ($MILLION)
  • TABLE 66: INDIA: TUMOR ABLATION MARKET SIZE, BY MODE OF TREATMENT, 2013-2020 ($MILLION)
  • TABLE 67: INDIA: TUMOR ABLATION MARKET SIZE, BY APPLICATION, 2013-2020 ($MILLION)
  • TABLE 68: ROAPAC: TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2013-2020 ($MILLION)
  • TABLE 69: ROAPAC: TUMOR ABLATION MARKET SIZE, BY MODE OF TREATMENT, 2013-2020 ($MILLION)
  • TABLE 70: ROAPAC: TUMOR ABLATION MARKET SIZE, BY APPLICATION, 2013-2020 ($MILLION)
  • TABLE 71: ROW: TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2013-2020 ($MILLION)
  • TABLE 72: ROW: TUMOR ABLATION MARKET SIZE, BY MODE OF TREATMENT, 2013-2020 ($MILLION)
  • TABLE 73: ROW: TUMOR ABLATION MARKET SIZE, BY APPLICATION, 2013-2020 ($MILLION)
  • TABLE 74: PIPELINE DEVELOPMENTS AND PRODUCT ENHANCEMENTS (2012-2015)
  • TABLE 75: DIVESTMENTS AND ACQUISITIONS (2012-2015)
  • TABLE 76: GEOGRAPHIC EXPANSIONS (2012-2015)
  • TABLE 77: AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS (2012-2015)
  • TABLE 78: OTHER DEVELOPMENTS (2012-2015)

LIST OF FIGURES

  • FIGURE 1: RESEARCH DATA
  • FIGURE 2: MARKET SIZE ESTIMATION
  • FIGURE 3: TUMOR ABLATION MARKET , BY COUNTRY/REGION (2015-2020)
  • FIGURE 4: TUMOR ABLATION MARKET: REGIONAL SCENARIO (2015)
  • FIGURE 5: GLOBAL TUMOR ABLATION MARKET FUTURE TRENDS, BY MODE OF TREATMENT AND APPLICATION (2015-2020)
  • FIGURE 6: MARKET EVOLUTION
  • FIGURE 7: KEY TUMOR ABLATION MARKETS: CHANGING PROPORTION OF GERIATRIC INDIVIDUALS IN TOTAL POPULATION (2012 VS. 2020)
  • FIGURE 8: GLOBAL PREVALENCE OF CANCER: EXPECTED TREND TILL 2020
  • FIGURE 9: PERCENTAGE CHANGE IN HEALTHCARE EXPENDITURE: DEVELOPED VS. DEVELOPING NATIONS (2010-2012)
  • FIGURE 10: VALUE CHAIN ANALYSIS
  • FIGURE 11: TUMOR ABLATION MARKET, BY TECHNOLOGY: GROWTH FORECAST DURING 2015-2020
  • FIGURE 12: TUMOR ABLATION MARKET SHARE FOR RF TECHNOLOGY, BY REGION (2015)
  • FIGURE 13: TUMOR ABLATION MARKET SHARE FOR MICROWAVE TECHNOLOGY, BY REGION (2015)
  • FIGURE 14: TUMOR ABLATION MARKET SHARE FOR CRYOABLATION TECHNOLOGY, BY REGION (2015)
  • FIGURE 15: TUMOR ABLATION MARKET SHARE FOR OTHER TECHNOLOGIES, BY REGION (2015)
  • FIGURE 16: TUMOR ABLATION MARKET, BY APPLICATION: GROWTH FORECAST DURING 2015-2020
  • FIGURE 17: TUMOR ABLATION MARKET FOR SURGICAL MODE OF TREATMENT, BY REGION (2015)
  • FIGURE 18: TUMOR ABLATION MARKET FOR LAPAROSCOPIC MODE, BY REGION (2015)
  • FIGURE 19: TUMOR ABLATION MARKET FOR PERCUTANEOUS MODE, BY REGION (2015)
  • FIGURE 20: TUMOR ABLATION MARKET, BY APPLICATION: GROWTH FORECAST DURING 2015-2020
  • FIGURE 21: TUMOR ABLATION MARKET SHARE FOR LIVER CANCER, BY REGION (2015)
  • FIGURE 22: TUMOR ABLATION MARKET SHARE FOR LUNG CANCER, BY REGION (2015)
  • FIGURE 23: TUMOR ABLATION MARKET SHARE FOR KIDNEY CANCER, BY REGION (2015)
  • FIGURE 24: TUMOR ABLATION MARKET SHARE FOR BONE METASTASIS, BY REGION (2015)
  • FIGURE 25: TUMOR ABLATION MARKET SHARE FOR OTHER APPLICATIONS, BY REGION (2015)
  • FIGURE 26: NORTH AMERICA: TUMOR ABLATION MARKET, EXPECTED TREND (2015 VS. 2020)
  • FIGURE 27: NORTH AMERICA: TUMOR ABLATION MARKET SHARE, BY TECHNOLOGY, 2015
  • FIGURE 28: U.S.: TUMOR ABLATION MARKET SHARE, BY TECHNOLOGY (2015)
  • FIGURE 29: U.S.: TUMOR ABLATION MARKET SHARE, BY MODE OF TREATMENT (2015)
  • FIGURE 30: U.S.: TUMOR ABLATION MARKET SHARE, BY APPLICATION (2015)
  • FIGURE 31: CANADA: TUMOR ABLATION MARKET SHARE, BY TECHNOLOGY (2015)
  • FIGURE 32: CANADA: TUMOR ABLATION MARKET SHARE, BY MODE OF TREATMENT (2015)
  • FIGURE 33: CANADA: TUMOR ABLATION MARKET SHARE, BY APPLICATION (2015)
  • FIGURE 34: EUROPE: TUMOR ABLATION MARKET, EXPECTED TREND (2015 VS. 2020)
  • FIGURE 35: EU-5: TUMOR ABLATION MARKET SHARE, BY TECHNOLOGY, 2015
  • FIGURE 36: ITALY: TUMOR ABLATION MARKET SHARE, BY TECHNOLOGY (2015)
  • FIGURE 37: ITALY: TUMOR ABLATION MARKET SHARE, BY MODE OF TREATMENT (2015)
  • FIGURE 38: ITALY: TUMOR ABLATION MARKET SHARE, BY APPLICATION (2015)
  • FIGURE 39: GERMANY: TUMOR ABLATION MARKET SHARE, BY TECHNOLOGY (2015)
  • FIGURE 40: GERMANY: TUMOR ABLATION MARKET SHARE, BY MODE OF TREATMENT (2015)
  • FIGURE 41: GERMANY: TUMOR ABLATION MARKET SHARE, BY APPLICATION (2015)
  • FIGURE 42: FRANCE: TUMOR ABLATION MARKET SHARE, BY TECHNOLOGY (2015)
  • FIGURE 43: FRANCE: TUMOR ABLATION MARKET SHARE, BY MODE OF TREATMENT (2015)
  • FIGURE 44: FRANCE: TUMOR ABLATION MARKET SHARE, BY APPLICATION (2015)
  • FIGURE 45: U.K.: TUMOR ABLATION MARKET SHARE, BY TECHNOLOGY (2015)
  • FIGURE 46: U.K.: TUMOR ABLATION MARKET SHARE, BY MODE OF TREATMENT (2015)
  • FIGURE 47: U.K.: TUMOR ABLATION MARKET SHARE, BY APPLICATION (2015)
  • FIGURE 48: SPAIN: TUMOR ABLATION MARKET SHARE, BY TECHNOLOGY (2015)
  • FIGURE 49: SPAIN: TUMOR ABLATION MARKET SHARE, BY MODE OF TREATMENT (2015)
  • FIGURE 50: SPAIN: TUMOR ABLATION MARKET SHARE, BY APPLICATION (2015)
  • FIGURE 51: ROE: TUMOR ABLATION MARKET SHARE, BY TECHNOLOGY (2015)
  • FIGURE 52: ROE: TUMOR ABLATION MARKET SHARE, BY MODE OF TREATMENT (2015)
  • FIGURE 53: ROE: TUMOR ABLATION MARKET SHARE, BY APPLICATION (2015)
  • FIGURE 54: ASIA-PACIFIC: TUMOR ABLATION MARKET, EXPECTED TREND (2015 VS. 2020)
  • FIGURE 55: ASIA-PACIFIC: TUMOR ABLATION MARKET SHARE, BY TECHNOLOGY, 2015
  • FIGURE 56: JAPAN: TUMOR ABLATION MARKET SHARE, BY TECHNOLOGY (2015)
  • FIGURE 57: JAPAN: TUMOR ABLATION MARKET SHARE, BY MODE OF TREATMENT (2015)
  • FIGURE 58: JAPAN: TUMOR ABLATION MARKET SHARE, BY APPLICATION (2015)
  • FIGURE 59: CHINA: TUMOR ABLATION MARKET SHARE, BY TECHNOLOGY (2015)
  • FIGURE 60: CHINA: TUMOR ABLATION MARKET SHARE, BY MODE OF TREATMENT (2015)
  • FIGURE 61: CHINA: TUMOR ABLATION MARKET SHARE, BY APPLICATION (2015)
  • FIGURE 62: INDIA: TUMOR ABLATION MARKET SHARE, BY TECHNOLOGY (2015)
  • FIGURE 63: INDIA: TUMOR ABLATION MARKET SHARE, BY MODE OF TREATMENT (2015)
  • FIGURE 64: INDIA: TUMOR ABLATION MARKET SHARE, BY APPLICATION (2015)
  • FIGURE 65: ROAPAC: TUMOR ABLATION MARKET SHARE, BY TECHNOLOGY (2015)
  • FIGURE 66: ROAPAC: TUMOR ABLATION MARKET SHARE, BY MODE OF TREATMENT (2015)
  • FIGURE 67: ROAPAC: TUMOR ABLATION MARKET SHARE, BY APPLICATION (2015)
  • FIGURE 68: ROW: TUMOR ABLATION MARKET, EXPECTED TREND (2015 VS. 2020)
  • FIGURE 69: LEADING MARKET PLAYERS ADOPTED PRODUCT DEVELOPMENT AND COMMERCIALIZATION AS KEY GROWTH STRATEGIES DURING 2012-2015
  • FIGURE 70: TUMOR ABLATION MARKET SHARE, BY KEY PLAYER (2014)
  • FIGURE 71: KEY GROWTH STRATEGIES, BY YEAR
  • FIGURE 72: PRODUCT DEVELOPMENT, THE MOST WIDELY ADOPTED GROWTH STRATEGY DURING 2012-2015
  • FIGURE 73: TOP 5 PLAYERS GENERATED MORE THAN 3/5TH OF THEIR GLOBAL TUMOR ABLATION REVENUE FROM AMERICAS *
  • FIGURE 74: TECHNOLOGICAL DEVELOPMENT AND PRODUCT ENHANCEMENT IS THE KEY STRATEGY PURSUED BY TOP PLAYERS TOINCREASE THEIR TUMOR ABLATION MARKET REVENUE
Back to Top